The document discusses improving patient engagement in clinical trials through digital methods. Only 2-5% of cancer patients currently participate in clinical trials. The top 3 solutions identified to engage patients were: 1) a clinical trial finder for patients to inform them of available trials, 2) virtual clinical trials conducted entirely online, and 3) tools to personalize clinical trials to individual patient needs/preferences. The document reviews several companies providing these types of solutions and proposes an experiment partnering with a CRO to test if a digital intervention increases patient enrollment and retention in a clinical trial compared to a control group without a digital intervention.
The Patient-Centered Clinical Trial: A New ParadigmJohn Reites
Patient centricity is no longer just viewed as an opportunity
solely for commercial pharma. In September 2014,
eyeforpharma brought together 100 US clinical leaders
to discuss the evolving role of patients in clinical trials.
The executive forum addressed the latest trends and
innovations in clinical trial management from a patientcentric
perspective, but it was the presence and involvement
of several patients and patient advocates that shaped the
discussion and expanded our thinking on the topic. Beyond
debating various practical questions, delegates from
pharma began to wonder how the necessary changes might
materialize under the organizational lens.
Mosio's Clinical Trial Patient Recruitment and Retention Ebook (First Edition)Mosio
The first edition of Mosio's patient recruitment and retention ebook contains 68 tips and examples from clinical research industry professionals on ways to improve efforts to recruit, retain and engage clinical trial patients.
To get access to a free download of the 2nd Edition, visit http://www.mosio.com/prebook
For more information on how you can improve patient engagement while increasing workflow efficiencies in communicating with study participants using two-way text messaging, please visit us at http://www.mosio.com
The Patient-Centered Clinical Trial: A New ParadigmJohn Reites
Patient centricity is no longer just viewed as an opportunity
solely for commercial pharma. In September 2014,
eyeforpharma brought together 100 US clinical leaders
to discuss the evolving role of patients in clinical trials.
The executive forum addressed the latest trends and
innovations in clinical trial management from a patientcentric
perspective, but it was the presence and involvement
of several patients and patient advocates that shaped the
discussion and expanded our thinking on the topic. Beyond
debating various practical questions, delegates from
pharma began to wonder how the necessary changes might
materialize under the organizational lens.
Mosio's Clinical Trial Patient Recruitment and Retention Ebook (First Edition)Mosio
The first edition of Mosio's patient recruitment and retention ebook contains 68 tips and examples from clinical research industry professionals on ways to improve efforts to recruit, retain and engage clinical trial patients.
To get access to a free download of the 2nd Edition, visit http://www.mosio.com/prebook
For more information on how you can improve patient engagement while increasing workflow efficiencies in communicating with study participants using two-way text messaging, please visit us at http://www.mosio.com
Closing the Loop: Strategies to Extend Care in the EDEngagingPatients
This HIMSS15 presentation discusses the challenges faced in hospital emergency departments and offers insights for implementing a process to follow up with discharged ED patients to enhance outcomes and satisfaction,while optimizing utilization and reducing risk.
Safety is Personal: Partnering with Patients and Families for the Safest CareEngagingPatients
The work of NPSF"s Lucian Leape Institute's Roundtable on Consumer Engagement, "Safety Is Personal: Partnering with Patients and Families for the Safest Care" is a call to action for health leaders, clinicians, and policy makers to take the necessary steps to ensure patient and family engagement at all levels of health care.The report identifies specific action items for health leaders, clinicians, and policy makers to pursue in making patient and family engagement a core value in the provision of health. care.
In first of two-part series, Pamela Greenhouse explores the differences and similarities of the Patient and Family Centered Care Methodology and Practice (PFCC M/P) and leean process improvement approachs, such as Lean, Six Sigma and Toyota. She believes that the PFCC M/P can be the unifying theme for health care, incorporating both process improvement and performance improvement.
Clinical practice guidelines and quality metrics often emphasize effectiveness over patient-centered care. In this article, the authors offer three approaches to personalizing quality measurement to ensure patient preferences and values guide all clinical decisions.
Redefining the role of patient support programs: Shifting the focus towards p...SKIM
Presented by:
Alex Zhu, Manager
Ariel Herrlich, Analyst
The recent shift toward consumerism and patient empowerment is driving companies to reevaluate the role and design of patient support programs. Historically, pharmaceutical manufacturers implemented support programs largely as a way to address patient non-adherence.
These programs were often single-based solutions designed to meet mass market needs. Next generation patient support programs will go beyond simple adherence to address holistic disease management through individualized, patient-centric service offerings.
Using a case study, we illustrated:
- How to evaluate your current patient support program offerings, using a combination of standard and non-standard metrics and exercises
- Re-define what “value” means in a world of patient-centricity and personalized care
- Assess the impact/ROI of potential new service offerings and enhancements
IMS Health Clinical Trial Optimization SolutionsQuintilesIMS
IMS Health's Linda T. Drumright, general manager, Clinical Trial Optimization Solutions presents at the 3rd Annual Patient Recruitment & Retention Summit 2014 - San Francisco, CA
This resource summarizes the eight recommendations outlined in the Institute of Medicine's a new consensus study entitled, Improving Diagnosis in Health Care. The recommendations are aimed at making diagnoses more accurate, reliable, efficient, and safe. This work is a continuation of the IOM’s Quality Chasm series.
Tricks of the Trade: Patient Recruitment & Retention for Different Study TypesImperial CRS
In efforts to raise the bar for medical advancement, clinical trials are growing increasingly complex. This complexity, more often than not, leads to costly delays in enrollment. In this ebook, we'll take a look at 4 case studies for different study types, and examine the unique factors to consider during planning.
Closing the Loop: Strategies to Extend Care in the EDEngagingPatients
This HIMSS15 presentation discusses the challenges faced in hospital emergency departments and offers insights for implementing a process to follow up with discharged ED patients to enhance outcomes and satisfaction,while optimizing utilization and reducing risk.
Safety is Personal: Partnering with Patients and Families for the Safest CareEngagingPatients
The work of NPSF"s Lucian Leape Institute's Roundtable on Consumer Engagement, "Safety Is Personal: Partnering with Patients and Families for the Safest Care" is a call to action for health leaders, clinicians, and policy makers to take the necessary steps to ensure patient and family engagement at all levels of health care.The report identifies specific action items for health leaders, clinicians, and policy makers to pursue in making patient and family engagement a core value in the provision of health. care.
In first of two-part series, Pamela Greenhouse explores the differences and similarities of the Patient and Family Centered Care Methodology and Practice (PFCC M/P) and leean process improvement approachs, such as Lean, Six Sigma and Toyota. She believes that the PFCC M/P can be the unifying theme for health care, incorporating both process improvement and performance improvement.
Clinical practice guidelines and quality metrics often emphasize effectiveness over patient-centered care. In this article, the authors offer three approaches to personalizing quality measurement to ensure patient preferences and values guide all clinical decisions.
Redefining the role of patient support programs: Shifting the focus towards p...SKIM
Presented by:
Alex Zhu, Manager
Ariel Herrlich, Analyst
The recent shift toward consumerism and patient empowerment is driving companies to reevaluate the role and design of patient support programs. Historically, pharmaceutical manufacturers implemented support programs largely as a way to address patient non-adherence.
These programs were often single-based solutions designed to meet mass market needs. Next generation patient support programs will go beyond simple adherence to address holistic disease management through individualized, patient-centric service offerings.
Using a case study, we illustrated:
- How to evaluate your current patient support program offerings, using a combination of standard and non-standard metrics and exercises
- Re-define what “value” means in a world of patient-centricity and personalized care
- Assess the impact/ROI of potential new service offerings and enhancements
IMS Health Clinical Trial Optimization SolutionsQuintilesIMS
IMS Health's Linda T. Drumright, general manager, Clinical Trial Optimization Solutions presents at the 3rd Annual Patient Recruitment & Retention Summit 2014 - San Francisco, CA
This resource summarizes the eight recommendations outlined in the Institute of Medicine's a new consensus study entitled, Improving Diagnosis in Health Care. The recommendations are aimed at making diagnoses more accurate, reliable, efficient, and safe. This work is a continuation of the IOM’s Quality Chasm series.
Tricks of the Trade: Patient Recruitment & Retention for Different Study TypesImperial CRS
In efforts to raise the bar for medical advancement, clinical trials are growing increasingly complex. This complexity, more often than not, leads to costly delays in enrollment. In this ebook, we'll take a look at 4 case studies for different study types, and examine the unique factors to consider during planning.
A Pharmaceutical Industry's Role in Clinical Trial Improvement.pdfSollers College
The drive to quickly develop a vaccine in record time should concentrate attention on common bottlenecks in the clinical trial process, as well as steps that the life sciences industry could take to reduce those bottlenecks and speed up the process for other drug candidates.
Clinical trials are necessary for medical research. Producing new medicines to the market depends on the strength of research organizations and drug companies to test and verify their work vigorously through their Clinical Trials, but finding people willing to participate is notoriously tricky.
New Technologies Close the Recruitment GapJohn Reites
Applied Clinical Trials (15Sep2014)
Optimizing Patient Enrollment in Global Clinical Trials
Overcoming enrollment issues due to changes in country requirements, how to create less burdensome global protocols with the patient in mind, how to decrease the cost of medicines and care, how to incorporate local assessments/reduce travel, mobile technologies used in global enrollment procedures and the potential of registries to enhance recruitmentless
Big data, RWE and AI in Clinical Trials made simpleHadas Jacoby
Technology is slowly but surely penetrating the healthcare industry in general and the clinical trials sector in particular. New and advanced solutions offer a variety of possibilities aimed to both improving existing processes and creating new and more efficient ones. And on top of all stands the desire to make clinical trials more patient centric.
In all of this, even though some of the technologies have yet to mature enough to meet the high quality standards necessary, it is important to know them and begin imagining the promise they hold for clinical trials.
Clinical Research Informatics World 2015Jaime Hodges
Complementing their exceptional series of informatics programming in Boston this spring, Cambridge Healthtech Institute and Clinical Informatics News are proud to launch Clinical Research Informatics World. The event brings together industry leaders, innovative thinkers and decision makers in the areas of clinical operations, clinical trial management, clinical innovation, data analysis, clinical trial informatics, data management, clinical research IT, and clinical information systems for two days of dynamic discussions, expert-led presentations and invaluable networking.
The 2015 program featuring a plenary keynote session and two concurrent conference tracks provides coverage on such topics as big data use and analytics for advancing clinical research, data visualization and analysis trends, new technologies in use for clinical trials (including mobile technology, wearables and social media), and cross-industry data sharing. Learn more at http://www.clinicalinformaticsworld.com
Real world Evidence and Precision medicine bridging the gapClinosolIndia
Real-world evidence and precision medicine represent complementary forces reshaping the healthcare landscape. The synergy between these realms offers a pathway to more personalized, effective, and patient-centered care. As technology, data analytics, and collaborative initiatives advance, the integration of real-world evidence into precision medicine practices holds the promise of revolutionizing how healthcare is delivered, ensuring that treatments are not only scientifically sound but also tailored to the unique characteristics and experiences of individual patients.
Strong recruiting techniques and Strategies for Clinical Trials begin with the patient as the center of attention and use a range of outreach approaches that are aimed to educate and engage prospective participants.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Telehealth Psychology Building Trust with Clients.pptx
Patient engagement in clinical trials
1. Partnering with
Patients for Clinical
Trials
2016 A HealthXL Report on improving patient engagment in clinical trials
The Leading Global Platform for Digital Health Collaboration
2. 2
Table of Contents
Editorial
The Challenge
Catalysing the Community: Clinical Advisors
Marketplace Review
Suggested Experiment
Your Personalised View of the Digital Health Market
Appendix 1 - Market Breakout
3
4
5
7
11
12
14
3. 3
Editorial:
Patients as Partners in Clinical Trials
Only 2-5% of adult US cancer population is enrolled in Clinical Trials
The pharmaceutical research enterprise is under tremendous pressure to innovate in order
to discover new drugs and commercialize their portfolio more effectively. The average cost
to develop a drug is $2.6 Billion and takes 10 yearsi. This model is unsustainable. To make
matters worse, upon launch, enterprises learn that patients may not value the intervention
as expected.
Traditionally, clinical trials have suffered from a number of challenges including enrolling
patients, identifying trial sites, reducing study drop-off rates, to name a few. 80% of industry
clinical trials do not meet patient recruitment timelines and the current drop-off rate across
all trials is 30%. There is also increasing pressure on clinical trial providers to become
“patient centric”, to leverage technology, and to push the envelope on how health is
measured.
What’s the solution? How does one create a more effective research enterprise? The answer
is more straightforward than we might think – partner with patients. Lets make patients
consider clinical trials a care option.
A number of key trends make this easier. First of all, patients are more self empowered than
ever before and are seeking to get involved. Solutions can further streamline the process by
meeting patients where they are – making the clinical trials easy, convenient, and
accessible . Virtual clinical trials, remote data capture via wearables, and research through
care delivery are just a few things that can delight patients while improving the overall
research process.
For example, in the area of oncology, a number of care solutions aimed at providers capture
tumor type underlying genetics, and treatment effectiveness – which can act as parameters
to assess trial eligibility. Further, a number of patient communities and real-world evidence
solutions enable researchers to access patients and learn about patient’s needs more
directly, and even enable patients to co-design studies.
With all the changes happening within clinical trials, we invite you to read this report that
highlights a number of solutions and approaches to next-generation clinical trials.
4. 4
HealthXL Challenge
Improve patient engagement in clinical trials by creating a landscape in which it is
simple for a patient to find and participate in a clinical trial. Patients consider clinical
trials as a care option and have the power to find out themselves which clinical trial
they are eligible for.
Vision
Taking cancer patients as a model group, the challenge is to meet the planned
enrollment of patients in 90% of trials and to reduce patient ‘drop-off by 20% in trials
via the implementation of digital methods to improve the patient experience in
clinical trials.
Challenge
• Involve the patient at the earliest possible planning stages to ensure the trial
design and protocol will match a patient’s lifestyle and needs.
• Empower the patient to be able to identify the trails that he/she are eligible for
without the need to always go through clinical providers and clinicians.
• Explore other technologies that offer the patients the opportunity to connect and
engage more meaningfully with both clinical trial organisers and other patients.
Defining the challenge
5. 5
Industry Advisors
HealthXL has a large and growing community of advisors made up of clinicians, healthcare
industry professionals, venture capitalists, payors, serial entrepreneurs, and innovators.
The top experts in patient engagment in Clinical Trials within the HealthXL community are:
Catalysing the Community
Martin Kohn
Chief Medical Scientist
Sentrian
Martin Naley
Founder
Cure Forward
Colm Galligan
Medical Director
MSD
Dr Galligan has extensive experience
in setting up multinational phase 2,3 &
4 clinical trials as well as supporting
the development of Investigator
Sponsored studies
Dr. Kohn is an alumnus of MIT, Harvard
Medical School and NYU and is a fellow of
both the American College of Emergency
Physicians and the American College of
Physician Executives.
Martin is the founder of Cure Forward,
who help people get tested, get their
data, and then put their data to use to
understand their disease and find
options for treatment, including clinical
trials.
6. Brendan Buckley
Chief Medical Officer
Icon
Jamie Goldfarb
Patient Advocate
Cindy Geoghegan
Patient Advocate
Brendan has extensive experience in
clinical trials and chairs several
independent Data and Safety
Monitoring Boards for medium to
large cardio-metabolic and rare
disease clinical studies
Cindy and Jamie are both cancer
survivors, Cindy a breast cancer
survivor and Jamie melanoma. They
both now represent the patient
community as advocates, and each
participated in clinical trials that led to
the treatment of their cancer.
Industry Advisors
Catalysing the Community
6
7. 7
HealthXL reviewed the digital technology marketplace, focusing on companies that could
potentially address the Challenge set.
Solutions that addressed the challenge set were found to have one of more of he following
capabilities: patient finder for clinical trial (CT) organiser, CT finder for patient, CT finder for
physician, virtual clinical trial, tool to personalise clinical trial for patients, education, real
world data leverage, electronic informed consent software, ride share company to get
patient to CT.
Solutions that put the patient at the centre of the clinical trial were selected as the most
effective at engaging patients in clinical trials. HealthXL chose the top 3 capabilities
addressing patient engagement in clinical trials. They were 1) CT finder for patient, 2) virtual
clinical trial, 3) tool to personalize clinical trial for patient,.
Marketplace Review
CT finder for patient
Virtual clinical trial
Tool to personalize
clinical trial for patient
Online database of ongoing clinical trials informing patients what CTs specific
to their disease are available.
Clinical trial that is conducted online - from patient enrollment to measuring
biometrics, to monitoring progress.
Aids patient in finding clinical trial suited exactly to their disease
type and needs.
8. 8
Companies Designing Clinical Trials for Patients
Name
Science 37
Mytrus
ePatient
Finder
Patients Like
Me
Thread
Research
Circulation
VitalTrax
TrialX
Transparency
Life Sciences
See Appendix 1 for description of companies listed.
Software to
streamline
patient
recruitment
Database for
patients to source
clinical trials
Metasite
mobile based
CT paltform
Remote patient
reserch platform
Database for
patients to source
clinical trials
Leverages real
world oncology
data to improve
CT design
Electronic
informed
consent software
Ride share to get
patient to trial
site.
Connects
physicians to
CTs for their
patient
Crowd Sourced
Clinical Trials
platform
Writes and
organise CT info
in a easily
understandable
way
Patients educate
each other on
CTs available
Strata
Oncology
Match late stage
cancer patients to
clinical trials
Patient
Finder for
Clinical Trial
Organiser
Clinical Trial
Finder for
patient
Clinical Trial
Finder for
Physician
Virtual
Clinical Trial
Tool to
Personalise
Clnical Trial
for patients
Education Misc.
Flat Iron
Custodix
Custodix is the
driving force
behind real world
data collection
9. Patient
Finder for
Clinical Trial
Organiser
Clinical Trial
Finder for
patient
Clinical Trial
Finder for
Physician
Virtual
Clinical Trial
Tool to
Personalise
Clnical Trial
for patients
Education Misc.
9
Companies Designing Clinical Trials for Patients
See Appendix 1 for description of companies listed.
Crowdsourced
database of all
clinical trials
Assists in finding
personalised
CTs for patients
via Trial
Exchange
forum.
Cure
Forward
Kayentis
Open Trials
Antidote
FindmeCure
One Voice
Neoclinical
Clinithink
Double
Blinded
Trinetix
Molecular
Match
Connects patients
with clinical trials
Provides
genomic
sequencing test
for patient
Educates
patients on the
science behind
their cancer
Helps patients
understand
treatments that
are available
Patient
community for
Orphan Disease
patients
Database for
patients to source
clinical trials
Registered nurses
help patients to
find clinical trials
Provides lists of
patients based
on trial protocol
eligibility
Motivational
messages, alerts,
reminders,
integrated into
eCOA solution
Crowd Sourced
Clinical Trials
platform
Helps cancer
patients find CTs
Helps cancer
patients find CTs
Name
Through
screening and
referrals, finds
patients for CROs
Researchers can
see patients
with specific
genetic data on
Trial Echange
Forum.
10. 10
Capability CT finder for patient – informs
patient on ongoing CTs
Antidote connects patients with
clinical trials by organizing the
world’s research information and
presenting it to patients.
How do they
engage the
patient?
Partners
Based
Founded
Science 37 is a mobile based
clinical trials company that
removes geographical barriers
for patients allowing them to
bring research into their homes.
Cure Forward provides patients
with a genomic sequencing test
which they can use to find their
best suited clinical trial via
clinical trial exchange.
Antidote Match uses NLP and AI
to help people find their best
clinical trial match.
Antidote Connect Network is an
online network of health portals,
patient organizations and
advocacy groups aiming to
connect patients to clinical trials.
Mobile app Nora is a technology
platform that integrates
telemedicine technology into the
clinical research process enabling
patients to engage in remote
clinical trials.
JDRF, Healthline, CentreWatch,
GALAXY
Science 37 has 29 partners such
as Genentech, Novartis, Naked
Biome, Harvard Clinical Medical
Cureforward has 12 partners
including Novartis and Quintiles, 3
non-profit organisations such as,
Fight Colorectal Cancer and
Diagnostic Test Providers such as
Cynvenio.
UK and US California Boston
2010 2014 2014
Virtual Clinical Trial Tool to personalize clinical
trial for patient
Cure Forward’s process is 3
steps:
1.Patient receives genomic
sequencing
2.Patient receives test results
3.Patient can post themselves of
clinical trials exchange to find
best suited trial.
Company
Deep Dive
11. 11
Suggested Experiment
Using a digital health solution improves patient engagement in clinical trials. Patient
recruitment for clinical trials will increase and patient drop off during clinical trials will
decrease.
Working with a Contract Research Organisation the hypothesis would be tested in a
two-armed randomized control oncology trial. Recruitment of oncology patients will
be conducted.
• Control Group – Cancer patients that are recruited without using a digital
intervention, and are not given a digital intervention during the trial.
• Study Group – Cancer patients that are recruited using a digital intervention and
are given a digital intervention during the trial.
• Study length – 6 months, day 1 is the first day patient recruitment for clinical trial.
Show interest
Interested in this challenge?
Hypothesis
Methods
Primary Endpoints:
Taking cancer as a disease category of interest, HealthXL proposes the following
experiment:
• Number of study group patients vs control group patients that enrolled for clinical trial
• Number of of study group patients vs control group patients that stayed in clinical trial
for study length.
12. 12
Bloomberg meets LinkedIn for digital health
The HealthXL Platform brings together key market stakeholders in digital health, and
empowers them to collaborate and learn from each other
• Gain global coverage of market intelligence for innovative high growth companies
• Access shared strategic learnings from market thought leaders
• Close the loop for new collaborative projects, bringing together customers, solutions,
funders and precise expertise
HealthXL Members:
Request to join the HealthXL Platform today at manage.healthxl.co
Join today
13. 13
With thanks to our member Icon
for proposing this challenge
Authors
Ruth Coleman
Lead Market Analyst, HealthXL
ruth@healthxl.org
Julie Carty
Head of Member Engagement,
HealthXL
julie@healthxl.org
References
i. 2016, Tufts Centrer for the Study of Drug Development
ii. Fouad et al., 2013. Enrollemnt of patients with lung and colorectal cancers onto clinical trials.
Journal Of Oncology
Michael Garrow
Business Analyst, HealthXL
michael@healthxl.org
Carlos Rodarte
HealthXL Advisor
rodarte.carlos@gmail.com
“ The importance of patient engagement in clinical trials shouldn’t be underestimated. Where
patients have been engaged in clinical trial design in particular it has proven to substantially
improve patient recruitment, retention and overall compliance rates. Wearables continue to grow
in their importance in clinical trials capturing more data more accurately while acting as a real-
time source of information to patients”.
Tom O’ Leary, Chief Information Officer at Icon
14. 14
Flat Iron is a cloud based software that support the continuum of cancer care.
It organizes the world’s oncology information.
Vitaltrax in a cloud based software solution that gives patients guidance with
access to clinical trial information and also has eCOA and EDC features.
Double Blinded is a crowdsourced clinical trials platform. Their primary
focus is to provide users with a reliable way to determine the effective ness
of a given lifestyle decision.
Transparency life sciences is an online network that aim to design clinical trials
via crowdsourcing methods and provide open access to clinical trial data
without limitations.
Trinetx is a federated data network that connects clinical researchers in real
time to the patient populations they are attempting to study.
Science 37 is a mobile based clinical trials company that allows patients to bring
research into their homes.
FindMeCure is the “google for clinical trials” - users can search, weigh, and
understand treatments in development
Companies 1/3
Appendix 1
PatientsLikeMe is an online network of over 400,000+ patients who can share their
knowledge on treatment options, ongoing research, and support each other.
15. 15
Appendix 1
Molecular match helps cancer patients find all trials available for their
specific type of cancer.
Strata oncology's goal is to expand late stage cancer patients access to tumor
sequencing and precision medicine trials.
TrialX is building an ecosystem of solutions to build a robust online presence
for clinical trials.
ePatientfinder connects physician’s and EHR data to clinical trials
Antidote connects patients with clinical trials by organizing the world’s research
information and presenting it to patients.
Thread Research is a Turn Key Remote Patient Research and Care Software
that enables remote patient research via Apple Researchkit and Carekit.
Companies 2/3
Neoclinical is a group of registered nurses that match patients with clinical trials.
Kayentis design eCOA solutions that are designed to improve clinical trial
compliance with solutions that are intuitive, efficient and user friendly for patients.
16. 16
Appendix 1
Cure Forward provides patients with a genomic sequencing test which they
can use to find their best suited clinical trial via clinical trial exchange.
Clinithink is CLiX ENRICH for Clinical trails interrogates rich patient data from
within EMRs, PROs and and EDC systems to optimize patient recruitment
processes.
Circulation is a non-emergency medical transportation service that through its
partnership with Uber can assist in physically getting patients to trial sites.
Companies 3/3
OneVoice is a platform for encouragement, knowledge and collaboration in
rare diseases. Their platform rareClnical provides information on ongoing rare
disease clinical trials.
Mytrus has developed enroll – a mobile informed consensus and patient
enrollment platform for clinical trials.
Custodix is a soltuion that collects and shares privacy senstive data. It is the
driving force behind the InSite Platform which aims to accelate clinical research
by leveraging Real World Data.